FDA Clearance Tracker · P170034
HYDRUS MICROSTENT
Last checked: Nov 19, 2026Latest source record: Aug 10, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Aug 10, 2018
Approved
Time to decision
284 days
Received Oct 30, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P170034
- Device name
- HYDRUS MICROSTENT
- Applicant
- Alcon Research, LLC
- Applicant location
- Fort Worth, TX
- Received
- Oct 30, 2017
- Decided
- Aug 10, 2018
- Decision
- Approved
- Supplements
- 17 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the Hydrus® Microstent. This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OGO. The earliest in FDA's data is P000026, decided Jul 12, 2001.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Alcon Research, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P230012 · Decided Aug 26, 2024 · 524 days after receipt
Device type: Gases used within eye to place pressure on detached retina (LPO) · Ophthalmology
P220030 · Decided Jul 2, 2024 · 564 days after receipt
Device type: Gases used within eye to place pressure on detached retina (LPO) · Ophthalmology
- LEGION System510(k)
K191650 · Decided Nov 1, 2019 · 134 days after receipt
Device type: Unit, Phacofragmentation (HQC) · Ophthalmology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.